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Our trails and trials in the subsarcolemmal cytoskeleton network
and muscular dystrophy researches in the dystrophin era
By Eijiro OZAWA*1,†
(Communicated by Kunihiko SUZUKI, M.J.A.)
Abstract: In 1987, about 150 years after the discovery of Duchenne muscular dystrophy
(DMD), its responsible gene, the dystrophin gene, was cloned by Kunkel. This was a new substance.
During these 20 odd years after the cloning, our understanding on dystrophin as a component of the
subsarcolemmal cytoskeleton networks and on the pathomechanisms of and experimental
therapeutics for DMD has been greatly enhanced. During this paradigm change, I was fortunately
able to work as an active researcher on its frontiers for 12 years. After we discovered that dystrophin
is located on the cell membrane in 1988, we studied the architecture of dystrophin and dystrophin-
associated proteins (DAPs) complex in order to investigate the function of dystrophin and
pathomechanism of DMD. During the conduct of these studies, we came to consider that the
dystrophin–DAP complex serves to transmembranously connect the subsarcolemmal cytoskeleton
networks and basal lamina to protect the lipid bilayer. It then became our working hypothesis that
injury of the lipid bilayer upon muscle contraction is the cause of DMD. During this process, we
predicted that subunits of the sarcoglycan (SG) complex are responsible for respective types of
DMD-like muscular dystrophy with autosomal recessive inheritance. Our prediction was conﬁrmed
to be true by many researchers including ourselves. In this review, I will try to explain what we
observed and how we considered concerning the architecture and function of the dystrophin–DAP
complex, and the pathomechanisms of DMD and related muscular dystrophies.
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1. Background: Studies on muscular dystrophy
in the pre-dystrophin era
1.1. Clinical and pathological aspects. Mus-
cular dystrophy is a group of genetic diseases encom-
passing 40–50 disorders, the symptoms of which are
characterized by chronic generalized progressive
atrophy of skeletal muscles. Among them, Duchenne
muscular dystrophy (DMD), which is inherited in an
X-linked recessive manner1) is the most prevalent
worldwide. Disturbance of walking and running
appears at the age of 3–5 years, loss of ambulation
by the age of 15 years and being bed-bound there-
after.
Most symptomatologies1) and pathological
changes2) of DMD were described in the 19th
century. By the middle of 20th century, the mild
type of DMD, namely, Becker muscular dystrophy
(BMD), and autosomal recessive Duchenne-like
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glycanopathy) which shows symptoms and course
close to DMD were unambiguously described. In
20th century, especially in its later half, various
congenital muscular dystrophies (CMD) were de-
scribed.
1.2. Biological studies of muscular dystrophy
in the pre-dystrophin era. Presence of aldolase at
higher levels in serum from patients with muscular
dystrophy was described by Lehninger3) in 1949.
Extending this ﬁnding, Ebashi4) together with Sugita
discovered high serum creatine kinase (CK) level in
patients in 1959. This has been used worldwide for
biochemical examination of muscular dystrophy and
other muscle diseases. At the same time, this ﬁnding
triggered the classical biological research on these
diseases. Serum CK has been considered to be
derived mostly from the living muscle ﬁbers leaking
through the cell membrane. Later, many soluble
cytoplasmic enzymes and proteins,5) such as myoglo-
bin, were found to be released from DMD muscle
ﬁbers.
Mostly in 1970s, many important studies were
described, some of which are still worthy of being
seriously considered. (1) Movement, namely muscle
contraction, is an important risk factor of DMD. In a
short term experiment,6) the serum CK level of a
DMD patient, whose baseline serum CK value at rest
was already about one hundred times higher than
that of normal boys, increased by about ten times
from his baseline levels, when he visited the zoo.
Myoglobin was similarly increased. (2) In DMD
muscle, tiny tears on the lipid bilayer of the cell
membrane were found by electron microscopy
(EM).5) (3) Total calcium ions in DMD muscle ﬁbers
were found to be increased.5) (4) Calcium–calpain
hypothesis was formulated7) (see Discussion (5)).
However, further elucidation of these phenomena
in causal relation to DMD was not feasible. Back
then, DMD was only understood based on the
complicated clinical and pathological ﬁndings, but
the essence to connect such phenomena speciﬁcally to
DMD was lacking. The classical DMD researches
obviously came up against a wall and stayed there for
a decade.
2. The beginning of the dystrophin era
In 1987, the wall was broken out by “laypersons
of the medicine”. The responsible gene for DMD was
discovered by young basic scientists, in spite of
absence of knowledge on the responsible protein.
This brought about a great revolution of the research
not only of DMD but also of many genetic diseases.
Soon, a number of new groups having various
backgrounds of new biology joined in the research
and grew to its mainstream. In this review, I
summarize mainly our works and thoughts developed
together with the progress of the new era. However,
our works were related to those of others. To avoid
confusion and to separately understand the works
from each laboratory, I used the laboratory chiefs’
names to designate works cited. The names of the
ﬁrst authors of those works are found in the
references.
2.1. The dystrophin and utrophin genes. In
1983, Davies, Kunkel and Worton started to search
for the responsible gene for DMD under the auspices
of the Muscular Dystrophy Association of America.
In 1987, Kunkel ﬁrst cloned the gene,8),9) which was
then named the dystrophin gene. Dystrophin was a
new substance. Some characteristics of the gene and
its products and other related matters are described
here for better understanding of this review
(Fig. 1).8),9) The dystrophin gene is localized at
chromosome Xp21, its size is 3 megabases, occupying
about 1/1,000 of the total genome size, and is
composed of 79 exons. The size of the mRNA is
14kb. The number of amino acid (AA) residues in
dystrophin is 3,685, as deduced from the nucleotide
sequence, and it has a molecular weight of 427kDa.
Dystrophin is a roughly slender protein. The primary
sequence of the N-terminal portion is highly homol-
ogous to those of the N-terminal portion of ,-actinin,
and this portion was named the actin-binding
domain (AB domain: AA #14–240, exons 2–8).
Tandem domains of this region are the rod or triple
helical segment (AA #253–3040, exons 8–61), the
Fig. 1. Dystrophin: Molecular domains and functional domains.
AB-D: actin-binding domain that binds to .-actin ﬁlament
composing the subsarcolemmal cytoskelton network. Rod: also
termed ‘triple helical segments.’ The rod contains AB-S (another
binding site to .-actin) encoded by exons (EX) 38–40. CR:
cysteine rich domain. C-ter: C-terminal domain. DGBD:binding
site on dystrophin for O-DG. Hot Spot 1 & 2: the sites that are
deleted with high frequency in the dystrophin gene. The
frequency of mutation in Hot Spot 2 is much higher than that
in Hot Spot 1. AA #: Range of AA residues, spanning each
domain.
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exons 62–69) and ﬁnally the C-terminal domain (AA
#3361–3685, exons 69–79). The length of the rod
was assumed to be 125nm. Four potential small
hinges were found in the rod. This molecular
structure was constructed on the basis of the analogy
of dystrophin and ,-actinin, and dystrophin was
initially considered to be present as an anti-parallel
homodimer until 1997, except ourselves (see Dis-
cussion (2)).
Later in 1996, Ervasti10) reported the presence of
a second binding site for actin ﬁlament in the middle
of the rod of dystrophin. The binding site exists in
AA #1416–1880 (exons 32–40) that corresponds to
the triple repeat numbers 11–14 (Fig. 1). In this
review, I tentatively call this site “the AB site” to
discriminate this site from “the AB domain” at the
N-terminus of dystrophin.
In 1989, Davies cloned the utrophin gene that is
mapped to 6q24.11) Its identities to dystrophin are
about 65% and 80% at the nucleotide and AA levels,
respectively. Utrophin is expressed on the cell
membrane of myotubes and is replaced by dystrophin
as diﬀerentiation progresses.
In 1989, in the dystrophin gene of mdx mice, a
nonsense mutation was discovered at nucleotide
#3185.12) It is known that mdx mice lack dystrophin
in muscle cells and show the dystrophic pathology in
muscle. They have widely been used as an animal
model of DMD.
2.2. Works of our project team: localizing
dystrophin to sarcolemma. Back in October 1983,
I met Kunkel for the ﬁrst time in a symposium held
in Pennsylvania, where he gave a talk on his initial
trials on the dystrophin gene cloning. After the
meeting, I sometimes read papers reporting the
course of cloning trials of this gene published from
Davies, Kunkel and Worton groups. In the mean-
while, I mulled over the future tide of DMD
research. “Sooner or later, the dystrophin gene must
be cloned. After the gene is cloned, the next main
‘battleﬁeld’ would no doubt be protein studies. In
the biochemical studies, it is prerequisite to have a
tool for detecting the protein, namely, to generate
antibodies against the protein product of the
dystrophin gene. To get antigen for dystrophin, we
should synthesize polypeptides in accordance with
the AA sequence deduced from the nucleotide
sequence of the dystrophin gene that must be
published in the near future. Once I have synthe-
sized the polypeptides, their antibodies would easily
be obtained.” In this context, I approached the
Central Research Institute (CRI) of Ajinomoto Co.
regarding the synthesis of the polypeptides, as a
collaborative work. CRI has an excellent team for
peptide synthesis headed by Eguchi. “The ﬁrst work
to be done should be the determination of the
dystrophin locus in muscle ﬁbers, which should
provide the basis for dystrophin studies in various
aspects.” Because I imagined that there must be
many researchers worldwide who had the same idea,
not wasting time was absolutely necessary for this
study. Unfortunately, at that time our group did not
have experience with immunohistochemical tech-
niques. Thus, I decided to collaborate with Arahata
who had good experience in the techniques in
Sugita’s laboratory, just next door.
In the middle of June 1987, I proposed this
collaborative project to Sugita. After I scrupulously
explained this project to him, he at last agreed to my
proposal. The muscle samples were to be provided
by Nonaka. Thus, the project team of three
laboratories of our institute and a laboratory of
CRI started.
In the July 31 issue of Cell in 1987, I read
Kunkel’s paper reporting the partial AA sequence
of dystrophin.8) Immediately, I instructed Eguchi
to start the polypeptide synthesis. Soon after, he
produced and sent me two polypeptide fragments of
dystrophin with 50 AA residues. Then, our team
obtained two polyclonal antibodies against these
polypeptides by conventional methods. Using these
antibodies, Arahata stained the normal and DMD
muscles. Our dystrophin antibodies clearly stained
the sarcolemma in normal human but not in DMD
in January 1988 (Fig. 2A & C). Thus, absence of
dystrophin on the sarcolemma was the cause of
DMD. In addition to this, Arahata observed that
dystrophin was distributed evenly throughout the
sarcolemmas of human skeletal muscles without
discriminating red and white muscle ﬁbers. The ﬁrst
paper on localization of dystrophin was published in
the February 1988 issue of this journal (PJA).13)
Luckily enough, our next paper similar to the PJA
paper was published in Nature on June 30, 1988.14)
No similar paper had yet been published from other
laboratories, before our papers.
Function of dystrophin was at that time
unknown. However, because our results were com-
patible with the hypothesis on the sarcolemmal
injury as the cause of DMD that was widely
believed in the pre-dystrophin era, our results were
soon accepted. This method has been widely used
both for DMD diagnostics and basic research on
E. OZAWA [Vol. 86, 800dystrophin including the gene therapy study of
DMD. In any case, our results indicated the
direction of my following studies, i.e., how dystro-
phin is associated with the cell membrane, and what
is its function, which when defective must cause
DMD.
2.3. Sarcolemma. In the following description,
the term sarcolemma is used to designate the basal
lamina, lipid bilayer and subsarcolemmal cytoskele-
ton networks together (Fig. 3B). This usage is
rational, because this term was ﬁrst used by Bowman
in 1840 to designate the amorphous structure present
on the surface of the muscle ﬁber.
The lipid bilayer is the sole layer among the
sarcolemma that serves as the barrier to maintain the
intracellular environment constant, because ionized
substances are not permeable. Thus, its intactness is
prerequisite for keeping life for the cell. However, the
lipid bilayer that is penetrated with a lot of proteins
is mechanically weak. Thus, the muscle ﬁber upon
contraction threatens its own life by generating
strong tension.
The basal lamina is a thick and mechanically
tough sheet that extracellularly attaches to the lipid
bilayer, but is permeable to various molecules
including proteins.
The subsarcolemmal cytoskeleton networks
present beneath the lipid bilayer of muscle ﬁbers,
especially at costamere, contain a number of .-actin
ﬁlaments.15) The .-actin ﬁlaments are connected to
desmin by plectin to form the main components of
the networks that form the lining of the lipid bilayer.
It was known from the early days of new era that
the .-actin ﬁlament serves as a scaﬀold for the
N-terminus of dystrophin. Unfortunately, only a
few EM studies of the subsarcolemmal cytoskeleton
networks in relation to dystrophin have been
made.16),17)
Shortly, the basal lamina and the subsarcolem-
mal cytoskeleton networks mechanically protect the
lipid bilayer.
2.4. The Kunkel model of dystrophin attach-
ment to the cell membrane in 1988. Kunkel’s
paper18) reporting the presence of dystrophin on the
cytoplasmic surface of the sarcolemma was published
in the same issue of Nature as our paper above-
mentioned.14) At the end of 1988, Kunkel19) published
a hypothetical model of how dystrophin is placed on
the sarcolemma, based on the following: (1) that
dystrophin does not have a membrane spanning
domain; (2) an assumption, that dystrophin is a long
molecule and thus must be ﬁxed at both ends: (2a)
the N-terminus must bind to an actin ﬁlament and
(2b) the C-terminus must bind to an imaginary
“integrated membrane protein” (IMP); and (3) an
assumption that dystrophin is present as an anti-
parallel dimer as described above. The assumption
(3) obligatorily results in that dystrophin has binding
sites to IMP at its both ends and is attached parallel
to the cell membrane. This Kunkel model was
composed only of IMP present in the lipid bilayer,
dystrophin dimer and actin ﬁlaments (cf. Fig. 3A;
The basal lamina, including laminin, and ,-DG
drawn in this ﬁgure, were not included in the Kunkel
model).
When Kunkel published this model, no exper-
imental data to show the existence of the IMP was
available. However, this model greatly inﬂuenced on
the formation of the 1991-models of Campbell and
later models of ourselves as explained below.
2.5. Our main works (1): Immunohistochem-
istry. Having introduced the immunohistochemical
techniques into my laboratory, we carried out various
studies, including developmental expression of dys-
trophin20) but I will cite here only those closely
relevant to this review.
In 198921) and 1991,22) we discovered that
utrophin is expressed on the sarcolemma of DMD
human and mdx mouse muscles in place of dystrophin
(Fig. 2). In 199323) and 1994,24) we found that O-
dystroglycan (O-DG; the dystrophin binding protein
Fig. 2. Reciprocal localization of dystrophin and utrophin on
normal and DMD human sarcolemma. A & B, normal muscle;
C & D, DMD muscle; A & C, anti-dystrophin antibody staining;
and B & D, anti-utrophin antibody staining.
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DMD and mdx muscles but is clearly present on the
sarcolemma. Because utrophin is anchored to O-DG
in DMD muscle, utrophin must be distributed less
densely on DMD sarcolemma than dystrophin
present on normal sarcolemma.
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Fig. 3. Dystrophin models and dystrophin bolt. A. Antiparallel dimer model. C-terminal (CT) domain and AB domain (ABD) are
present at both ends of antiparallel dimer oriented dystrophin ﬁxed by respective IMP. Although this ﬁgure is drawn as if two
dystrophin molecules were composed of solid metal that were attaching throughout, how these long molecules were attached to each
other and to IMP was not well considered. Note that in this model, dystrophin is ﬁxed in parallel to the lipid bilayer and perpendicular
to IMP. This imaginary ﬁgure was drawn based on the models of Kunkel19) and Campbell29) and with binding of ,-DG to laminin
taken into consideration. For details see the text. B. Monomer model. Three strata of the sarcolemma, namely, an actin ﬁlament in the
subsarcolemmal cytoskeleton networks, lipid bilayer and basal lamina, are stitched and ﬁxed by dystrophin:O-DG:,-DG.50),51) These
three proteins, dystrophin:O-DG:,-DG, altogether are considered as a functional unit and termed the dystrophin bolt. Thus, an actin
ﬁlament and laminin serve as scaﬀolds of dystrophin bolt. When dystrophin is replaced by utrophin, the utrophin bolt composed of
utrophin:O-DG:,-DG is formed. Because the function of the dystrophin bolt and that of the utrophin bolt are qualitatively the same,
they together are termed ﬁxation bolts in this review.
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protein (DAP) complex and its architecture
3.1. Our main works (2): Biochemical puri-
ﬁcation of dystrophin and DAPs. Our modiﬁca-
tion of Campbell’s method. We started to develop
puriﬁcation methods for dystrophin in 1988, soon
after our studies localized it on the sarcolemma.
However, Campbell’s ﬁrst paper25) on the prepara-
tion of dystrophin and many other proteins that were
copuriﬁed with dystrophin was published in Nature
on March 16, 1989.
Campbell at ﬁrst prepared the sarcolemmal
fraction from rabbit muscle. Then, its lipid bilayer
was dissolved with a detergent, digitonin. The
resulting membrane proteins were fractionated using
a Wheat-germ agglutinin (WGA) column and anion
exchange column, followed by anti-dihydropyridine-
receptor (DR) antibody column. His ﬁnal sample
showed about 20 bands upon SDS polyacryl amide
gel electrophoresis (SDS PAGE) in addition to the
dystrophin band. Some of them were glycoproteins
that must be membrane-integrated or extracellular
proteins.
Soon, we adopted his method with some
modiﬁcations.26) After the WGA and anion exchange
column separation procedures, we used a gel ﬁltra-
tion column instead of the anti-DR antibody column.
Our ﬁnal sample was assumed to contain about 10
proteins (Table 1), judging from the bands that were
separated by SDS PAGE in addition to the band
corresponding to dystrophin. We conﬁrmed that
some of them were glycoproteins.
We then found that on treatment with a protein
cross-linker, bis-(sulfosuccinimidyl) suberate, all of
these proteins excluding A2 formed a huge cross-
linked product that moved only a short distance from
the original level by SDS PAGE. This suggested that
these proteins were directly or indirectly associated
with dystrophin excluding A2. However, we later
showed that A2 indirectly bound to dystrophin.
In 1990, after we submitted our manuscript,
Campbell published his second paper27) on a revised
protein preparation method. By this revised method,
he also obtained about 10 protein bands in addition
to dystrophin band. He showed the association of
dystrophin with these proteins in a way diﬀerent
from ours.
Although Campbell also obtained about 10
bands similar to us, it was soon revealed that
individual proteins discovered by both groups were
not completely the same (Table 1). In our ﬁrst
biochemical analysis, we did not ﬁnd Campbell’s
156DAG (,-dystroglycan, ,-DG). In Campbell’s list,
our A0 (dystrobrevin-1) was not included. Further-
more, although Campbell reported in 1990 that
43kDa proteins migrated as a doublet, he reported
in 199228) that these two proteins were immunolog-
ically indistinguishable, concluding that the doublet
was derived from a single protein. In contrast, we
tenaciously persisted with our claim since 1990 that
there are two types of 43kDa glycoprotein, namely,
A3a (O-dystroglycan, O-DG) and A3b (O-sarcoglycan:
O-SG) on the basis of isoelectric focusing analysis.
3.2. The Campbell 1991-model of the dystro-
phin–DAP complex and cloning of dystroglycan
gene in 1992. In the following description, I will use
the current terminology of dystrophin-associated
proteins (DAPs), although each DAP term was
coined later through several steps as our under-
standing of the characteristics of the DAP pro-
gressed.
Thereafter, Campbell published several papers
on dystrophin and DAPs. In Cell published in
1991,29) he classiﬁed dystrophin and DAPs into three
categories, namely, extracellular (,-DG), membrane-
integrated (,-SG, O-DG, .-SG and sarcospan) and
intracellular (dystrophin and dystrobrevin-1) pro-
teins, based on their experiments on membrane
Table 1. Dystrophin-associated proteins
Current terms Abbreviations
Previous terms Molecular weight
(kDa) Campbell Ozawa
,-dystroglycan ,-DG 156DAG — 156
O-dystroglycan O-DG 43DAG A3a 43
,-sarcoglycan ,-SG 50DAG A2 50
O-sarcoglycan O-SG — A3b 43
.-sarcoglycan .-SG 35DAG A4 35
/-sarcoglycan /-SG —— 35
sarcospan SPN 25DAP A5 25
dystrobrevin-1 DB-1 — A0 94
,-syntrophin ,-SYN 59DAP
A1
(acidic)
59
O-syntrophin O-SYN
A1
(basic)
62
Dystrobrevin-1 is the largest isoform of this protein. ,-
Syntrophin is an acidic protein, present abundantly on the
protoplasmic surface of the lipid bylayer. O-Syntrophin is a
basic protein, present almost restricted to the neuromuscular
junction. The preﬁxes , and O are often omitted, when
discrimination of ,- and O-syntrophin is not necessary.
Our trails and trials in cytoskeleton and muscular dystrophy researches in the dystrophin era No. 8] 803fractions treated with alkaline buﬀers. Extracellular
and the membrane-integrated proteins except sarco-
span were glycoproteins and could be stained with
lectins. All the glycoproteins except ,-DG were
stained by 3-triﬂuoromethyl-3-iodophenyl diazirine
(TID), a marker of the hydrophobic AA sequence
that spans the lipid bilayer. Sarcospan was unique
among the DAPs in that it was not glycosylated but
strongly binds to TID. Furthermore, he showed that
,-DG has both O-a n dN-sugar chains.
Then, he constructed his 1991-model, modifying
the Kunkel model on the basis of above ﬁndings.29)
Campbell replaced IMP with the above-described
four membrane-integrated proteins and putting ,-
DG on these proteins outside the sarcolemma. Thus,
his model was essentially similar to Fig. 3A, except
that the basal lamina including laminin was not
included. In addition, syntrophin was supposed to
bind with the intracellular domains of these mem-
brane-integrated glycoproteins. The binding partner
of dystrophin was not determined among DAPs.
The impact of his model, albeit immature, was
so strong that on seeing the model, many readers
took it as if he had actually determined all individual
protein–protein bindings depicted in the ﬁgure,
although he did not describe evidence to show that
he had determined those bindings. Contrary to this
tendency, Davies in her review30) provided a well-
reasoned critique discriminating between the ﬁndings
given by Campbell, by us and by others in 1994. This
review is important as an explanation and criticism of
the model by a third person.
In 1992, Campbell28) reported that ,-DG and O-
DG are encoded by a single gene, of which protein
product must be post-translationally processed,
although a cleavage site on the protein was not
known. He named the precursor protein dystroglycan
(DG). The processed proteins were called ,-DG
(156DAG) and O-DG (43DAG). Then, he showed
that native glycosylated ,-DG binds to laminin, a
major component of the basal lamina, in the presence
of calcium ions, whereas recombinant non-glyco-
sylated DG does not, suggesting that the extra-
cellular protein ,-DG connects to the basal lamina
via the sugar chains. This showed the connection of
the dystophin–DAP complex with the basal lamina.
Thus, he discussed as follows: “the function of
dystrophin is to link the subsarcolemmal cytoskele-
ton through a transmembrane complex to an
extracellular glycoprotein which binds laminin.”
Then, his model was redrawn similar to Fig. 3A
where IMP was composed of four proteins as
described above, namely, O-DG, ,-SG and .-SG
and sarcospan. But still, which DAG corresponds to
IMP and what portion of dystrophin binds to IMP
was not yet determined.
Initially, studies constructing the architecture
composed of the “native” dystrophin–DAP complex
were carried out by Campbell’s group. However, after
his 1991-model and DG cloning was published, with
some overlapped period, the study was mostly
succeeded by our group. It seemed to me that he
had a stronger interest in determination of the
characteristics of “individual” DAPs including their
gene cloning and in analysis of human clinical and
animal model materials with his antibodies rather
than in ﬁnding out new interactions between the
protein molecules of the complex. Thereafter, he
looked almost ceasing from exploring new protein–
protein interactions, until he only returned to this
study in 1997 (see below).
3.3. Our model of the dystrophin–DAP
complex in 2000. For a few years after establish-
ment of the puriﬁcation methods, we prepared for
promoting our study on the architecture of the
dystrophin-DAP complex.31) We considered that it is
inevitable to determine the binding partner of each
protein to construct the architecture. Because DAPs
are composed of about 10 kinds of protein, it is
diﬃcult to determine each binding partners using the
whole dystrophin-DAP complex or to search for each
pair with in vitro methods. Accordingly, we decided
to biochemically extract subcomplexes composed of a
few proteins from the whole complex, because bind-
ing partners can be easily determined from such small
subcomplexes. In addition, the bindings thus eluci-
dated must represent those working in vivo. Fur-
thermore, once the binding partners are determined
using native sample, details of each binding can easily
be analyzed by in vitro techniques.
By means of this strategy, we got several
subcomplexes (Fig. 4A, B and C) and determined
the binding partners during 8 years since 1992. Each
time when we got new data, we constructed small
models for the subcomplexes. Based on them, we
further constructed and published our model taking
both the Kunkel and Campbell models into consid-
eration. Our model was constructed and repeatedly
revised step by step as our understanding progressed.
It is troublesome to show each of our models at
diﬀerent stages. Here, I show only our ﬁnal model
published in 2000,32) which was revised later by
addition of actin ﬁlament associated to the AB site as
described by Ervasti10) (Fig. 4D).
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model composed of the DAPs was constructed by
superimposing small models deduced from our sub-
complex preparations, as explained below in Our
Main Works (3), (4) and (6) (Fig. 4A, B and C). The
exceptions were the binding of dystrobrevin-1 with
syntrophin (syn*, gray oval) and that of sarcospan
with the SG complex (buried under the colored
part) that were discovered by Froehner33) and by
Campbell,34) respectively in 1997. On the other hand,
the dark parts of Fig. 4D were drawn in accordance
with the ﬁndings of other laboratories. All the
associations of DAPs to its adjacent structural
proteins were determined in other laboratories,
namely, the associations of dystrophin:actin, ,-
DG:laminin and syntrophin:nNOS were experimen-
tally determined by Perry,35) Campbell,28) and
Bredt,36) respectively.
Our initial descriptions on the protein binding
were not necessarily detailed, although we later
Fig. 4. Our model of the dystrophin–DAP architecture in 2000. IMP: integrated membrane protein. For other abbreviations, see
Table 1. For further details, see text. A: Models of the subcomplex architecture published in 1992–5. a: Subcomplex obtained by
proteinase treatment composed of a glycoprotein complex (blue box) including IMP and dystrophin fragments (35/38kDa fragments
spanning mainly CR domain expressed in red line).40) b: DF685 binds to O-DG, syntrophin (shown in yellow oval) and dystrobrevin in
overlay binding assay.42),57) For Syn* (gray oval) and (cc) (small box), see text. c: DF442 binds to O-DG (full binding) in overlay
binding assay.42) B: Subcomplexes derived from the dystrophin–DAP complex treated by octyl glucoside in 1994.52) a: The void
fraction of gel ﬁltrate that contained dystrophin, dystrobrevin-1 and syntrophin. b: the DG complex; c: the SG complex; and d:
sarcospan. C: Subcomplexes published in 2000.32) Complex a, b and c were constructed on the basis of the data obtained from the
experiment described in Our Main Works (6). The complex c was previously discovered by Campbell in 1997.33) D: The colored part of
this model was constructed in 2000 by superimposing our submodels, mainly those shown in A, B and C.
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the lapse of time, many of the bindings that we
determined were analyzed in detail by other re-
searchers, on which I reviewed elsewhere.37) In
constructing Fig. 4A and D, we included the detailed
binding site of dystrophin and dystrobrevin-1 re-
ported by Kunkel in 1997.38)
3.4. Our main works (3): Determination of
the binding domain of dystrophin to O-DG, the
most important interaction for understanding
the function of DMD. Back in 1992, while we39)
were examining the proteinase-sensitive loci of
dystrophin, we40) collected glycoproteins present in
the enzyme-treated dystrophin–DAP complex sam-
ple using a lectin column. We obtained a few types of
small fragment of dystrophin that bound to these
glycoproteins. We considered that the portion
common among these fragments must include the
domain by which dystrophin bound to IMP. We
examined these fragments using various anti-dystro-
phin antibodies and partially by AA analysis,40) and
found that these dystrophin fragments had molecular
weights ranging from 35 to 38kDa. We further
determined that the common portion spans a tiny
portion of rod, the CR domain and the initial portion
of the C-terminal domain. Therefore, the IMP
binding potion was not the C-terminus of dystrophin
and diﬀerent from the anticipations of Kunkel19) and
Campbell29) (Fig. 4A-a). It was located at more
proximal site of dystrophin.
Afewyearsbeforeourﬁndings,Kunkel41)pointed
out based on their dystrophin gene mutation analysis
that the nucleotide sequence corresponding to the CR
domainwas lacking in most DMD cases. On this basis,
we interpreted our own ﬁndings as follows: the
absence of this dystrophin binding site for IMP results
in the complete loss of dystrophin from the sarcolem-
ma leading to DMD.40) In other words, the absence of
binding between dystrophin and IMP makes dystro-
phin unable to be ﬁxed at the subsarcolemmal
cytoskeleton networks and loss of the connection
between actin ﬁlament and IMP causes the disease.
In 1994, to determine IMP, we42) constructed
various recombinant peptide fragments of dystrophin
that were considered to encompass the domain for
binding IMP (Fig. 4A-b and A-c). Using an overlay
binding assay method with these fragments, we found
that IMP is a single glycoprotein, O-DG. Dystrophin
must bind to the intracellular domain of O-DG.
Indeed, Campbell43) later showed that the intra-
cellular C-terminal 15 AA residues of O-DG binds to
the above described dystrophin fragment.
We42) further found that a fragment AA #3026–
3264 (DF264) bound to O-DG, but the binding was
weak (reduced binding), whereas a longer fragment
AA #3026–3442 (DF442) strongly bound to O-DG
(full binding). Later, we conﬁned the full binding
domain to AA #3026–3345.44) All of these fragments
included a small portion of the C-terminal portion of
the rod as later pointed out by others to be a part of
the WW domain, a protein–protein binding con-
sensus domain.
By specifying the AA residues of O-DG binding
domain (DGBD) and identifying the IMP as O-DG,
we came to the conclusion that dystrophin is ﬁxed to
the actin ﬁlament in the subsarcolemmal cytoskele-
ton networks at its N-terminus, as found by others,
and to a membrane-spanning protein O-DG at
DGBD. These two binding sites are the basis of
our understanding on dystrophin function and
DMD pathomechanism. This concept was used by
Takeda45) in 1998 for designing the micro-dystrophin
used for experimental gene therapy of DMD as
explained in Discussion (6). Thereafter, several pa-
pers from other laboratories elucidated the details
of the association between DGBD and O-DG using
various methods, including X-ray diﬀraction (for
review37)).
In 2004, we44) speciﬁed that physiological DGBD
has AA #3026–3345, namely, DGBD ranges from
the last 54 AA residues of the rod to the CR domain
excluding the last 15 AA residues. The end of this
physiological DGBD was determined by comparing
our data to the in vivo experiment of Chamberlain.46)
We further suggested that to convert from the
reduced binding to full binding, a certain intra-
molecular structure of this domain was required. As
for utrophin, which was shown also to bind to O-DG
in a few laboratories, we44) showed that the binding
aﬃnity of utrophin to O-DG is about one half that of
dystrophin.
3.5. Discussion (1): Kunkel’s reading frame
rule from the viewpoint of protein–protein inter-
action. The relationship between the translational
reading frame and the AA sequence was already
known in 1960. What was new and important in
Kunkel’s work in 198847) was that he applied this
formula to the prediction of the relationship between
reading frame changes and the clinical severity of
patients with dystrophin gene mutations. His hy-
pothesis predicted that when the change in the
number of nucleotides in a mutation is 3N D 1o r
3N D 2 (N: integer), namely, out-of-frame mutation,
the down stream AA sequence changes and a stop
E. OZAWA [Vol. 86, 806codon is formed. Thus, a truncated dystrophin
missing the C-terminal side of the protein may be
generated. When the number changes by 3N (the N
of AA residues at the mutation site is deleted or
inserted) the downstream AA sequence does not
change except at the mutation site. Today, this
beautiful formula is often called the reading frame
“rule”. According to a recent report from a French
project team,48) among 2,084 independent mutational
events, the reading frame rule holds true for 96% of
DMD patients and 93% of BMD patients. However,
soon after Kunkel published this rule, Worton49)
reported exceptions to the rule in 1988 when a
mutation occurs at or close to the AB domain.
Since 1995,50) we repeatedly claimed that we
have to consider the reading frame rule on the basis
of changes in dystrophin at the protein level. As
stated above, when any of the structures that
mediate dystrophin binding to actin ﬁlaments or of
DGBD are defective, dystrophin cannot be ﬁxed to
the sarcolemma, resulting in the development of
DMD. I considered that the DMD cases with in-frame
mutations among Worton’s exceptions49) to the rule
must be due to the loss of function of dystrophin for
binding to an actin ﬁlament. However, this discussion
is not enough and for further details, see my review
published elsewhere.51)
In an in-frame mutation, the AA sequence is not
disturbed in the DGBD. Although the size of the rod
is decreased (or increased) in this case, dystrophin
can bind to the actin ﬁlament and O-DG and is
functional.
It is also important to consider that premature
stop codon mutations in dystrophin lead to nonsense
mediated decay (NMD) of the mRNA. If NMD
functions eﬃciently, the reading frame rule might be
explained by this mechanism in most cases, as little
mRNA of mutated dystrophin will become available
for translation by the ribosome. However, it is also
known that NMD is often not completely eﬃcient
and a surviving mRNA with a nonsense mutation
must be translated resulting in a defective dystrophin
protein lacking the DGBD. The function of such a
defective dystrophin must be considered as described
above.
3.6. Our main works (4): Discovery of the
DG and SG complexes. In 1994, we found the DG
and SG complexes,52) and a non-glycosylated (intra-
cellular) protein complex (Fig. 4B). These complexes
were obtained by treatment of the puriﬁed dystro-
phin–DAP complex with a detergent, n-octyl O-D-
glucoside, followed by fractionation using a gel
ﬁltration column.52) We coined the term sarcoglycan
(SG) at this time. The classiﬁcation of glycoproteins
into the DG and SG complexes was widely accepted
thereafter, and used as the standard classiﬁcation of
dystrophin-associated glycoproteins.
[1] The DG complex composed of ,-DG and O-
DG (Fig. 4B-b): As shown by Campbell28) in 1992,
they are encoded by a single gene and posttransla-
tionally processed. Here, we showed that these two
proteins are present forming a single protein complex
after processing, which we named ‘the DG complex’
after Campbell’s term DG. Campbell’s discovery is
concerning the genotype and synthesis of DG,
whereas ours is concerning the DG subcomplex in
the architecture of dystrophin–DAP complex at the
phenotype level.
[2] The SG complex (Fig. 4B-c): This complex is
now known to be composed of 4 subunits. We
initially considered that the SG complex was
composed of 3 subunits, ,-SG (A2 or 50DAG), O-
SG (A3b) and .-SG (A4 or 35DAG).52) We termed it
the sarcoglycan complex. Details of the character-
istics of these subunits were described elsewhere.53)
In 1996, Nigro54) cloned a new gene highly
homologous to .-SG and termed it /-SG (see below).
In collaboration with him, we55) showed that /-SG
(glycoprotein) is also contained in the puriﬁed SG
complex preparation. Therefore, the SG complex is
composed of four subunits. The molecular architec-
ture of the SG complex is described in Our Main
Works (6). The number of subunits forming the SG
complex does not change even after other two
subunits C-SG and 1-SG were discovered (for re-
view56)). These are not major components of the SG
complex in skeletal muscle.
Sarcospan was separated by octyl glucoside
treatment from the SG complex.
Each subunit of the SG complex and O-sugar
chains of ,-DG is responsible for 4 kinds of ARDMDs
(sarcoglycanopathy) and 6 kinds of CMDs, respec-
tively (see below). Sarcospan is not involved in the
cause of muscular dystrophy.
[3] The dystrophin–dystrobrevin–syntrophin
complex: In 1994, we52) detected dystrophin, dystro-
brevin-1 and syntrophin in the void fraction of gel
ﬁltration after treatment of the dystrophin–DAP
complex with n-octyl O-glucoside (Fig. 4B-a). It was
possible that these three proteins form a subcomplex,
because we had previously found that they were
included in the dystrophin–DAP complex.26) In 1994
in a separate work, we42) examined this question with
the overlay binding assay of these proteins using two
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DF442 and AA #3026–3685 (DF685: dystrophin
fragment spanning from DGBD to the terminus of
dystrophin molecule) (Fig. 4A-b and A-c). In addi-
tion to the binding to O-DG, DF685 bound to
dystrobrevin-1 and syntrophin, whereas DF442 did
not. Therefore, dystrobrevin-1 and syntrophin bind
to the C-terminal domain of dystrophin. In 1995,
we57) found that syntrophin bound to the dystro-
phin fragment AA #3443–3494. Simultaneously,
Kunkel58) also reported the same syntrophin binding
site of dystrophin. Furthermore, we57) found that
dystrobrevin-1 bound to the dystrophin fragment AA
#3495–3544 (Fig. 4A-b). In 1997, Kunkel38) speciﬁed
the binding sites to be the coiled-coil (cc) domains
present on both proteins, and Froehner33) found
binding of syntrophin (Syn*) to dystrobrevin-1 by
the overlay binding assay.
3.7. Discussion (2): The dystrophin bolt: A
complex of dystrophin and dystroglycans that
connect actin and laminin. The following items are
generally accepted: (1) Muscle ﬁbers contract gen-
erating force and heat. Upon contraction, chemical
energy contained in ATP is changed to the mechan-
ical energy that cannot be analyzed by biochemical
methods but by physiological methods.
(2) It is certain that muscle ﬁbers in health are
toughly constructed so as not to be injured by the
force generated during their contraction.
(3) It was becoming likely with time that
dystrophin and the glycoproteins do not have
biochemical activities, such as enzymatic activity.
(4) DMD ensues, when dystrophin and its
associated glycoproteins (DAG) are decreased or
lost. Dystrophin and DAG must be related to defects
of the tough construction of the muscle ﬁbers.
(5) Muscle contraction is a strong risk factor of
DMD. In other words, muscle ﬁbers are prone to
injury by contraction. The injury causes leakage of
soluble cytoplasmic proteins such as CK.5)
Taking these together, I consider that DMD is
primarily caused by impairment of some constituents
of a large architecture on the sarcolemma including
dystrophin, which must play essential roles in
preventing the cell body from injury by contractile
force. Thus, I conceived of a structure composed of
3 proteins, dystrophin, O-DG and ,-DG from the
architecture of the dystrophin–DAP complex
(Fig. 4D) and collectively named this triad the
dystrophin axis50) (this was later renamed the
dystrophin bolt59)). The dystrophin bolt transmem-
braneously connects subsarcolemmal cytoskeleton
networks with the basal lamina (Fig. 3B). An actin
ﬁlament and laminin serve as the scaﬀolds of the
dystrophin bolt. By stitching the networks and basal
lamina, the lipid bilayer that is inserted between
them can be mechanically and ﬁrmly protected. The
dystrophin bolt is distributed with a high density all
over the sarcolemma.13),14) In DMD muscle, dystro-
phin is replaced by utrophin with a low density,22)
whose binding ability to O-DG is weaker than that of
dystrophin.44) As shown by Davies,60) forced expres-
sion of utrophin in mdx mice rescued them from
muscle atrophy. Thus, the utrophin bolt, composed
of utrophin and ,-DG and O-DG, is functionally of
the same quality as the dystrophin bolt. Together
they both are called “ﬁxation bolts”.
In human DMD muscles, the dystrophin bolt is
lost but the utrophin bolt is weakly expressed.22)
Thus, the pathogenesis of DMD can be considered
primarily as functional insuﬃciency of the ﬁxation
bolt.
When dystrophin was discovered, it was claimed
that dystrophin assembles as an antiparallel dimer.9)
Both the Kunkel and Campbell models were con-
structed on the basis of this claim (see Fig. 3A). In
contrast, we considered that dystrophin is a mono-
mer on the basis of the EM observations on the
sarcolemma by Cullen17) in 1991. He showed that
gold-labeled anti-dystrophin antibody against the C-
terminus stained the site over or outside of the lipid
bilayer, whereas that against the rod (AA #1183–
1388. Roughly the middle of rod.) stained the deeper
position at 15–20nm (some bound as deep as at
75nm) from the lipid bilayer. In contrast to Cullen’s
discussion, we interpreted his observations that (1)
its C-terminus is located at close to the lipid bilayer,
(2) its N-terminal should present deeper apart from
the lipid bilayer and thus (3) dystrophin is present
in vivo as a monomer (see Fig. 3B). Dystrophin spans
between O-DG and an actin ﬁlament with some
angle to the lipid bilayer or with some bending of
dystrophin molecules probably at their hinges upon
relaxation, but may be turned and stretched perpen-
dicularly toward the sarcolemma by cytoplasmic ﬂow
upon contraction (see Discussion (3)).
While we used the monomer model in our
publications since 1994,50),61) Kunkel62) and Ervasti63)
independently showed in 1997 that dystrophin can be
present as a monomer. Then, Campbell also adopted
the monomer model, which was soon accepted
worldwide.
To determine whether dystrophin is an antipar-
allel dimer or a monomer is not merely of biochemical
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relation to the function of dystrophin. (1) In the
antiparallel dimer model (Fig. 3A), the AB domain
and C-terminus (Originally, the C-terminus was
assumed to be the IMP-binding site.) must be present
at both ends. Both ends of the dimer must be ﬁxed by
a transmembrane IMP, and must be closely localized
to the lipid bilayer. Thus, dystrophin must be ﬁxed
parallel to the lipid bilayer and roughly perpendicular
to IMP. In the dimer model, force directed to
dystrophin would not be eﬀectively conducted to
IMP. (2) In the monomer model (Fig. 3B), dystro-
phin DGBD binds to IMP (O-DG) and the AB
domain anchors to an actin ﬁlament located within
the length of dystrophin. Thus, dystrophin can be
ﬁxed roughly perpendicular to the lipid bilayer, at
least upon contraction. In other words, dystrophin
is ﬁxed extending strait from IMP to the subsarco-
lemmal network. In the monomer model, force
directed to dystrophin must be eﬀectively conducted
to IMP.
Needless to say, biomaterials are ﬂexible and not
the same as solid metals. However, I would like to
emphasize that a vertical component against the lipid
bilayer of the force given to dystrophin is eﬀectively
conducted to IMP, when the monomer model is
adopted. In this way, stitching of the three layers by
the dystrophin bolt can work well. Details of this
concept will be described in Discussion (3) and in
Discussion (4).
4. The second stage of the dystrophin era
In August of 1994, the 8th Neuromuscular
Congress, which is held once every four years, was
held in Kyoto. Almost all of the top researchers from
various ﬁelds of muscular dystrophy research, espe-
cially those of genetics, gathered together and
intensely discussed their recent progresses. New
leaders from new generations gave lectures on their
newly emerging ﬁelds of the science. This meeting
was an unprecedented success both in quality and
quantity.
Despite the success of the meeting, many
participants must have become aware that the tide
of muscular dystrophy research was clearly changing
from dystrophin genetics to many new directions.
Mainly, one was change in focus from gene to protein,
and the other was that from genetics of DMD to
those of other neurological disorders as well as other
muscular dystrophies. Trials on DMD gene therapy
were about to thrive, as the fundamentals for such
trials became available.
4.1. Our main works (5): Sarcoglycanopathy
(former ARDMD; SG-pathy): proposal and ver-
iﬁcation of a hypothesis. In 1992, Campbell64)
together with Fardeau showed that 50DAG was
absent from the cell membrane of ARDMD muscle
ﬁbers and Vance65) reported that the Tunisian
ARDMD locus mapped to chromosome 13. In the
next year, Zatz66) claimed that ARDMD is genet-
ically heterogenous, because some Brazilian ARDMD
gene loci did not map to 13q. Getting a hint from
these works, we examined whether ARDMD muscles
could be immunostained using 3 types of anti-SG
subunit antibodies. As expected, we found that all
three subunits were absent in the sarcolemma of
ARDMD muscle ﬁbers. Thus, it was likely that the
SG complex is responsible for ARDMD.
In accordance with this ﬁnding, we61) predicted
in 1994 immediately after the Kyoto meeting that if
any of the SG genes is mutated, its protein product is
missing, which then results in loss of the whole SG
complex, resulting in ARDMD. This may explain the
genetic heterogeneity.
In this statement, we had implicitly claimed that
the number of varieties of ARDMD must be the same
as that of subunits of the SG complex. All the
patients with varieties of ARDMD must be classiﬁed
according to the respective SG gene that is mutant.
This hypothesis further implicitly claimed that in the
case of ARDMD, we can clone each responsible gene
by a conventional method on the basis of the partial
AA sequences of each SG subunit, and the compli-
cated positional cloning method is not necessarily
required.
In 1994, the Campbell–Fardeau team67) cloned
an ARDMD responsible gene that mapped to
chromosome 17q21 and called this molecule “adha-
lin”. In 1995, the Kunkel–Ozawa team68) (We
provided partial AA sequences of A3b to Kunkel
who cloned the gene on the basis of the sequences)
and the Campbell–Beckmann team69) simultaneously
cloned the A3b gene. This gene was mapped to
chromosome 4q12 and mutations in the A3b gene
were found in the corresponding ARDMD patients.
The SG complex was also absent in the muscle ﬁbers
of these patients.
Based on the suggestion of the editor of Nature
Genetics to which both teams had submitted their
papers, Kunkel proposed a name for this molecule to
the relevant researchers including Campbell: Let us
name the present molecule O-SG. The names of the
molecules of this family should be called .- and /-SG,
etc. In this context, the term “adhalin” given to
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,-SG. His proposal was agreed on by all the
researchers involved in the cloning of these genes.
At that time of the proposal, the .-SG gene had
already been cloned in our laboratory,70) and other
necessary data were being collected in Kunkel’s and
Vance’s laboratories using materials from Hentati
and Middleton. It was mapped at 13q12 correspond-
ing to the Tunisean type of ARDMD.65)
In 1996, the gene for the fourth ARDMD was
mapped to chromosome 5q33 by Zatz.71) Independ-
ently, as described above, the /-SG gene was cloned
and was also mapped to chromosome 5q33 by
Nigro.54) They72) showed that the 5q33 mapping
patients had mutations on the /-SG gene. We, in
collaboration with Nigro,55) showed that its protein
product is actually present in a puriﬁed SG complex.
After a while, Zatz and Kunkel73) reported that in all
the cases originating from mutations in any of four
SG genes, the patient muscles lack the entire SG
complex by immunohistochemistry, although low
levels of some subunits are sometimes observed.
These studies conﬁrmed that our hypothesis61) was
true. Afterwards, I summarized these processes in
detail in a review published elsewhere.53)
Another claim, that the number of the types of
ARDMD that can be genetically discriminated is the
same as that of the SG subunits, was also considered
to be valid. It is because no new SG-pathy other than
these 4 types has been reported.
4.2. Our main works (6): Finalizing the
model of the architecture of the dystrophin–
DAP complex and the formation of the architec-
ture in development. [1] Finalizing our model of
the architecture of the dystrophin–DAP complex:
We obtained 3 subcomplexes from a puriﬁed dystro-
phin–DAP sample by the following treatment32):
(Fig. 4C) (1) The dystrophin–DAP sample was
incubated in 0.1M NaCl at pH 7.5 at 37°C for 6
hours and separated by gel ﬁltration chromatogra-
phy. One of the peaks was refractionated by gel
ﬁltration chromatography and ﬁnally the fraction for
the DG–SG–sarcospan complex (Fig. 4C-a) was
obtained. This was the ﬁrst direct evidence for the
association of the DG and SG complexes, although
their association had long been accepted without
doubt on the basis of some other indirect evidence.
(2) The dystrophin–DAP sample was incubated in
1M NaCl at pH 7.5 for 6 hours and separated by gel
ﬁltration chromatography. One of the fractions was
immunoprecipitated with anti-,-SG antibody and
the fraction for the syntrophin–dystrobrevin–SGs–
sarcospan complex (Fig. 4C-b) was obtained. Bind-
ing of dystrobrevin-1 to the SG complex must be
noted, because many of the current models ignored
this binding. Yoshida later gave deﬁnitive evidence
on the binding of syntrophin to dystrobrevin-1
(personal communication, unpublished data).
Although their in vitro binding was previously
described,33) the evidence for the binding from the
native complex was ﬁrst shown here. (3) The fraction
of (2) before immunoprecipitation was further
incubated with 1M NaCl for an additional 6 hours
and separated by gel ﬁltration chromatography
to obtain the SG-sarcospan complex (Fig. 4C-c):
this ﬁnal complex was previously reported by
Campbell.34)
In order to construct a model for the overall
architecture of dystrophin and DAPs, all the subunit
architectures illustrated in Fig. 4A, B & C were
superimposed on the actin ﬁlaments, the lipid bilayer
and the basal lamina. A larger protein architecture
model obtained on the basis of our data is shown as
the colored parts of the model in Fig. 4D, with a few
exceptions described above. Ten years have elapsed
since the publication of this model, and no modiﬁca-
tion of this colored model has been made.
[2] Developmental biology of the SG-complex:
At the early stage of myogenesis in vitro, when
myoblasts are predominant in a muscle cell culture,
we74) found that ,-, O-, .-a n d/-SG are detected at
both the mRNA and protein levels, although their
amounts are small. When myotubes are formed, the
expression level of all of the SG proteins increases
with those of other muscle-speciﬁc proteins. However,
their diﬀerential patterns at the level of SG mRNAs
were not the same. The expressed level of ,- and .-
SG mRNAs increased, whereas those of O- and /-SG
mRNAs did not, suggesting that the transcription of
,- and .-SG, and that of O- and /-SG are diﬀer-
entially controlled.
To clarify the problem of how ,-a n d.-SG
mRNAs are regulated, we75) studied the .-SG gene.
We observed that the .-SG mRNA promoter has an
E-box that is a consensus site for myogenic gene b-
HLH type protein, such as myoD, as well as an A/T-
rich element that binds to MEF2. These observations
suggest that expression of .-SG is regulated by classic
myogenic diﬀerentiation under the control of myo-
genic regulatory genes.
We76) found that at a speciﬁc stage of early
myogenic diﬀerentiation, it was possible to detect the
incompletely formed SG complex composed of a small
number of subunits binding to O-DG. We analyzed
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order of binding of the SG subunits to O-DG, as
shown in Fig. 5A. This was roughly compatible with
the report of Zatz and Kunkel73) who assumed the
order of SG complex formation from the residual of
SG subunit in SG-pathy muscle biopsy samples from
the patients. On the bases of our ﬁndings together
with their and Sakamoto’s reports,77) the SG complex
directly bound to O-DG with O- and /-SGs and then
.-SG and ﬁnally ,-SG (Fig. 5B). In the cases when 1-
and C-SGs are expressed, they may replace .- and ,-
SG, respectively, forming the diﬀerent SG complexes
with four subunits.
Generally, a membrane-integrated protein is
translated in the endoplasmic reticulum (ER) and
then transported to the Golgi apparatus. The
apparatus, in turn, is partially torn oﬀ to form
transport vesicles that are transported to the
sarcolemma. We76) analyzed the locus and the
process of formation of the complexes using brefeldin
A, which destroys the Golgi apparatus, and found
that DG and the SG subunits are all translated in the
ER. Both complexes are separately formed in the ER
as soon as their subunits are synthesized. In the Golgi
apparatus, the SG complex binds to both DG and
sarcospan to form a larger transmembrane complex,
which then becomes progressively glycosylated.
For the subsequent fate of this complex, based
on evidence observed by us76) as well as on the
general rule of protein synthesis, we can assume the
following. Dystrophin is synthesized in free ribosomes
and becomes associated through its DGBD to the
protoplasmic domain of O-DG that is already bound
to the SG complex in Golgi complex. After binding
dystrophin, the vesicles are transported to and fused
with the lipid bilayer, extruding dystrophin into the
protoplasma. Since the AB domain remains free, it
would bind to the subsarcolemmal actin ﬁlament
available for the length of dystrophin. This may be
the mechanism by which the dystrophin–DAP
complex is ﬁxed on the sarcolemma.
[3] Production of knock-out (KO) mice: During
this period, we78)–80) generated mice carrying KO
gene for the O-SG, .-SG or caveolin-3 gene. The
O-a n d.-SG KO mice showed muscular dystrophy
phenotypes, as described above. Caveolin-3 KO mice
showed only a limited muscular dystrophy pheno-
type.80)
5. My trials to elucidate the function of
dystrophin and the pathomechanisms of DMD
When I retired at the end of March 2000, 12
years had already elapsed since the discovery of
dystrophin. The main trend in DMD research in the
third stage was shifting to the experimental gene
therapy. Before and more frequently after my retire-
ment, I fortunately had chances to write compre-
hensive reviews,53),56),59),81) and chapters of large
books,5),37),51),82) on the dystrophin–DAP complex
and muscular dystrophies, and learned more cer-
tainly that the dystrophin–DAP complex is a
biochemically mute cytoskeleton component.
Accordingly, my question was why absence of
dystrophin causes progressive muscle atrophy, in
spite that dystrophin does not show any speciﬁed
function in vitro. It is current trend to search for a
biochemically active substance(s) as a responsible
factor(s) of DMD, which must secondarily be
disturbed due to absence of dystrophin. However,
these trials are not successful and almost no answer
to my question is available. Therefore, I must answer
to my own question on the basis of our works and
thoughts.
To answer this question, I tried to unite evidence
from various laboratories concerning (1) experimen-
tal studies on dystrophin and DAPs, especially of
molecular associations, (2) biology of muscle con-
traction that is a powerful risk factor of muscular
dystrophy, and (3) clinical observations and related
experimental studies including those derived in the
pre-dystrophin era. Although available evidence was
insuﬃcient and my explanations deduced from these
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Fig. 5. Formation of the SG complex. Sequence of binding of the
SG subunits. A. Sequence of formation of the SG complex. B.
Architecture of the SG complex that binds to O-DG. This model
was constructed on the basis of reports from several laboratories
including ours. Note that non-speciﬁc O- and /-SGs occupy
essential loci for the binding to O-DG, but muscle-speciﬁc .- and
,-SGs are placed outside.
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questions for future investigators.
5.1. Discussion (3): Further understanding
of function of the dystrophin bolt in relation to
muscle contraction in normal muscles. [1] The
dystrophin bolt functions in two ways: First, the
dystrophin bolt stitching the sarcolemma is diﬀusely
distributed throughout the sarcolemma, as explained
in Discussion (2) (Fig. 2 & 3B). Second, densely
located at the costameres, it also serves as a part of
larger structure that links the Z-bands of myoﬁbrils
and the basal lamina (Fig. 6A).51),83) Desmin–
vimentin intermediate ﬁlaments (DVIF)84) wind
around individual myoﬁbrils at the level of each Z-
band ﬁxing all myoﬁbrils together to form a myoﬁbril
bundle. These DVIF further radiate away from the
myoﬁbrils to the costamere, a condensed portion of
the subsarcolemmal cytoskeleton networks, where
DVIF indirectly connect to the dystrophin bolt. This
system was named the transverse ﬁxation system
(TFS),37) details of which were described else-
where.51) Thus, I understood that the dystrophin
bolt was a missing link of TFS that transmembra-
nously connects the DVIF and the basal lamina.
[2] Balooning of the sarcolemma on muscle
contraction: When we estimate a muscle ﬁber to be
a cylinder whose radius is r (r being 25–1007m), the
radius increases with contraction. When a sarcomere
(92.57m) shortens by 1/5, the radius increases to
1.12r, because the volume of the sarcomere remains
constant at least at the initial stage of contraction. If
we adopt the square pole model for a muscle ﬁber, the
result is similar. We must note that the increase of
the radius occurs within 10–20 milliseconds upon
contraction.
Upon contraction, the cylinder does not thicken
evenly along its length longitudinally (Fig. 6B),
because the radius does not increase at costameres
due to ﬁxation by the TFS. Instead, the radius
increases inbetween the costameres in a balloon-like
manner. Indeed, in longitudinal section of contracted
muscle ﬁbers display a repeating pattern of retrac-
tions and balloonings when observed by EM, a
pattern termed festooning.85) Note that because of
this retraction at the costameres, the total surface
area of the lipid bilayer is not decreased but is instead
stretched upon contraction.
[3] Myoﬁbrils, which are composed of a series of
sarcomeres, are the only machine that generates a
force that is exclusively directed along its longitudi-
nal axis. The force upon contraction is not primarily
directed toward the sarcolemma. Upon contraction,
all sarcomeres shorten similarly, the pressure inside
the adjacent sarcomeres simultaneously increases to
the same level. Cytoplasm in a given sarcomere
cannot longitudinally ﬂow to the adjacent sarcomere
over the Z-band. Thus, the cytoplasm must be forced
to move in a transverse direction to push the
sarcolemma outward. This movement gives rise to
festooning (Fig. 6B).
Almost no study is available on the cytoplasmic
movement upon contraction. It was known by X-ray
diﬀraction study of living skeletal muscle ﬁbers at
tetanus when shortening reached at the plateau, the
diameter of the cross section of sarcomeres increased
reversely proportional to the size of contraction
(eﬀect of constant volume of the sarcomere),86)
whereas in a saponin-treated (skinned) muscle ﬁbers,
whose lipid bilayer became permeable to cytoplas-
ma,87) the diameter remained almost similar to that
of the resting muscle.88) In my context, this diﬀerence
in diameter can be interpreted as follows: In the
skinned muscle ﬁbers in tetanus, the cytoplasm
squeezed from the shortened sarcomere must leak
extracellularly through the permeable sarcolemma
leaving the sarcomere diameter unchanged, whereas
in the intact muscle, the cytoplasm once squeezed out
of the shortened sarcomere would be forced back by
the elasticity of the sarcolemma making the diameter
larger. If this interpretation is the case, the approx-
imate volume of the cytoplasm can be assumed that
shuttles between inside and outside spaces of
sarcomere during the contraction-relaxation cycle.
Thus, the mean value of hydrodynamic pressure due
to movement of cytoplasm may be obtained by
studies on this line.
If the cytoplasm ﬂow pushed the lipid bilayer
very slowly in a quasi-static manner upon contrac-
tion, the pressure change would be slight and no
harmful damage would occur on the lipid bilayer.
However, because muscle contracts quickly and
cytoplasm must be rapidly forced out through narrow
clefts between the thin and thick ﬁbers of myoﬁbrils,
the hydrodynamic force applied to the lipid bilayer
by viscous cytoplasmic ﬂuid may become far larger
than the hydrostatic force.
[4] The muscle lipid bilayer has to bear the
hydrodynamic force upon contraction. To prevent it
from the destructive hydrodynamic force, it has a
robust protective system, as described above. In a
healthy muscle, this protective system must be
suﬃcient to resist mechanical stress of the cytoplas-
mic ﬂow. Thus, all the muscles of the body could
endure severe movements, such as athletics.
E. OZAWA [Vol. 86, 812Fig. 6. Transverse ﬁxation system (TFS). A. Molecular architecture of TFS: DVIF that surrounds and ﬁxes many myoﬁbrils (mf) at the
Z-band level and radiates outward to the sarcolemma. Roughly, desmin in the DIVF connects to actin ﬁlament in the subsarcolemmal
cytoskeleton networks via plectin, then to the dystrophin bolt which is ﬁnally ﬁxed to the basal lamina. It also connected to
dystrobrevin via syncoilin and/or O-synemin that bind to the C-terminal domain of dystrophin, which is ﬁnally ﬁxed to the basal
lamina via dystroglycan. PL, plectin; S, syncoilin and/or O-synemin; lam, laminin. For other abbreviations see Table 1. B. Function of
TFS: Festooning of the sarcolemma upon contraction observed in longitudinal section (B-b). a, relaxation; b, contraction; and c,
relaxation. Red bar on the lipid bilayer indicates the dystrophin bolt. Arrow in b: ﬂux of cytoplasm toward sarcolemma upon
contraction. Note that the sarcolemma balloons upon contraction owing to the ﬂux of the cytoplasm from the core of the muscle ﬁber.
However, at costameres, which are moored to the myoﬁbrils by TFS, the sarcolemma retracts. The ballooning of the sarcolemma
becomes ﬂat upon relaxation. For further details see the text.
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tations or thresholds for the CK leakage even in
healthy muscles. It is known that after severe
exercise, for example running 90km,89) serum CK
levels markedly increases to the levels found in DMD
patients, although there are some individual dif-
ferences. Serum CK levels return to the normal
baseline level within 2 days in normal subjects. This
suggests that some damage to the sarcolemma occurs
by severe exercise even in healthy persons.
[5] It has recently been discovered that the
sarcolemma is equipped with sarcolemmal membrane
repair machinery.90) This suggests that microtears of
the lipid bilayer occurring even in healthy muscle
ﬁbers, if they happen, are repaired quickly by this
machinery.
AllthephenomenadescribedaboveincludingDis-
cussion (2) are compatible with our working hypoth-
esis that dystrophin bolts that stitch the sarcolemma
mechanically protect the lipid bilayer from injury
that might occur upon contraction of the muscle.
5.2. Discussion (4): Hypothesis on the role of
protection systems for the lipid bilayer in the
pathomechanisms of DMD and some other
muscular dystrophies. Diﬀerence between normal
and DMD sarcolemma resides primarily in the
diﬀerence in strength of the ﬁxation bolts distributed
on the sarcolemma.
[1] Strenuous exercise for a DMD patient results
in a severe increase of serum CK and myoglobin
release from DMD muscle,6) even if it is not strenuous
for normal persons. Many soluble enzymes leak from
DMD muscles.5) These intracellular soluble proteins
are too large and lack hydrophobicity to pass through
the lipid bilayer, as long as the lipid bilayer is intact.
Increase of the release of soluble proteins describes
that the lipid bilayer in DMD muscle must be much
more easily injured than that in normal muscle,
forming microtears upon contraction allowing leak-
age of the soluble cytoplasmic proteins. However,
such microtears are so tiny and must be resealed very
soon and may not necessarily be revealed with EM, so
long as their sizes do not exceed the ability of the
repairing machinery. Such damages might better be
called “nanotears” rather than microters.
Experimentally, when the sarcolemma is sub-
jected to negative pressure by sucking with an
ultrathin glass tube, in other words, to an artiﬁcial
force directed outwards on the sarcolemma, the mdx
sarcolemma which lacks strong protective systems is
more easily damaged than the wild-type sarcolemma,
showing its mechanical fragility.91)
Shortly, microtear formation must be the ﬁrst
step of muscle damage leading to atrophy in DMD.
[2] The mutations that result in the dysfunction
of the dystrophin bolt cause other types of muscular
dystrophy with very high serum CK level.
[2A] DMD group: (1) A signiﬁcant decrease in
ﬁxation bolt causes DMD and BMD. The diﬀerence
in the symptomatology between DMD and BMD
may be due to the diﬀerence in the amount of the
ﬁxation bolt present in their muscles. (2) A decrease
in ﬁxation between dystrophin and O-DG in the
absence of the SG complex92) may cause 4 kinds of
SG-pathy.53)
[2B] CMD group: Mutation of the DG gene may
be embryonic lethal. The connection between the O-
sugar chain of ,-DG and laminin28) is prerequisite for
the function of the dystrophin bolt. Failure in the
connection causes CMD.
(1) The sugar sequence of the O-sugar chain of
,-DG, composed of 4 sugar molecules, was deter-
mined by Endo in 1997.93) Six CMDs have been
associated with the disturbance in sugar chain
synthesis. This results in weak connection between
the ,-DG and laminin. These CMDs are muscle–eye–
brain disease, Fukuyama-type CMD, Walker–
Warburg syndromes 1 & 2, Fukutin-related protein
deﬁciency and LARGE (for review94)).
(2) The absence of laminin ,2 (merosin), the ,-
dystroglycan scaﬀold protein, causes CMD.95)
Roughly, these 7 types of CMDs and 4 types of
SG-pathy can be discussed in a similar manner to
those of DMD on the basis of the above-mentioned
discussion for DMD, because the dystrophin bolt is
impaired due to a weak or absent binding to laminin
and thus cannot function suﬃciently to prevent
damage of the lipid bilayer.
One question is why the muscle damage appears
in the intra-uterine stage in these CMDs and in the
childhood in DMD, in spite that muscle ﬁbers of both
diseases have insuﬃciency of the ﬁxation bolt. This
diﬀerence can be ascribed to the diﬀerence in the
defective portion of the ﬁxation bolt.37),51) In DMD
and SG-pathies, intracellularly the connection be-
tween the subsarcolemmal cytoskeleton networks and
O-DG is defective but weakly present, whereas in
these CMDs, extracellularly that between ,-DG and
laminin is defective (cf. Fig. 3B).
In in utero normal development, the utrophin
bolt at ﬁrst appears in myotube stage and is replaced
by the dystrophin bolt before birth. Thus, the
utrophin bolt with lower density is switched to the
dystrophin bolt with higher density to bear the
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ment of the body.
In these CMDs, the connection between ,-DG
and laminin is defective both in utero and after birth,
regardless of switch from the utrophin bolt to the
dystrophin bolt. The basal lamina with defective
ﬁxation easily exfoliates from the lipid bilayer, which
becomes exposed to risk of injury even by weak
movements in utero. Thus, the myotubes and muscle
ﬁbers of the CMD fetus can be easily injured. Stunted
development of the muscles may occur. Thus, the
symptoms are noticed at or soon after birth of the
patients. Indeed, in merosin-deﬁcient CMD cases,
partial loss of the basal lamina is sometimes
observed,59) and the degree of muscle atrophy was
mild, when the basal lamina was well preserved.96)
In DMD, the utrophin bolts, even though they
are present only at lower density, work to ﬁx the
sarcolemma to some extent (Fig. 2). Immediately
after birth, while the patient moves only weakly, the
symptoms do not become apparent. But when the
patient starts to walk, run and jump, the sarcolemma
ﬁxed by the utrophin bolt becomes not strong enough
to bear his violent movements. Thus, the lipid bilayer
may be injured and atrophy and weakness of the
muscles gradually appear.
Thus, DMD, SG-pathy and these CMDs can be
summarized as “ﬁxation bolt insuﬃciencies” that
eventually induces injury of the lipid bilayer.
[3] In 2006, a mouse was reported with a
mutation in the choline kinase gene that results in
a decrease in phosphatidyl choline levels and
disruption of the lipid bilayer in muscle ﬁbers as
observed in DMD muscle ﬁbers.97) This mouse
showed a muscular dystrophic muscle phenotype
and elevated serum CK levels, even though dystro-
phin was present at the sarcolemma. Although many
questions remain to be answered, the existence of
muscular dystrophy due to abnormality of a compo-
nent of the lipid bilayer strongly supports my central
idea that the essential cause of muscular dystrophy is
repeated disruptions of the lipid bilayer.
5.3. Discussion (5): The next step after
microtear formation that leads to muscle atro-
phy. When microtear formation and repair of the
lipid bilayer occurs repeatedly, how do muscle ﬁbers
atrophy? Atrophy may be caused by loss of
cytoplasm, or by disturbance of either synthesis or
degradation of proteins or both.51)
[1] It is possible that leakage of soluble cytoplas-
mic enzymes and other proteins, if the amount lost is
large, may have some inﬂuence on the decrease in
the cell volume, their catalytic processes and other
functions. In addition, because AA derived from
degraded proteins is used for synthesis of new
proteins, recycling of AA in protein turnover may
be disturbed, if the protein leaks chronically and
large amounts of proteins are lost. But even if this
occurs at a high level, this might not be the sole cause
of muscle atrophy.
[2] For increased digestion of proteins, the
calcium–calpain hypothesis was proposed in the
1970’s.7) This hypothesis states that through minute
pores of lipid bilayer, CaDD ions from the extra-
cellular ﬂuid enter into the cytoplasm. Then, CaDD
ions activate calpain, a calcium-activated neutral
protease. Activated calpain, in turn, digests muscle
proteins leading to muscle atrophy. This idea on the
mechanisms underlying DMD has long been believed
worldwide. This may be one of the probable
hypotheses. However, it seems to me that this
hypothesis is too preliminary to be accepted as the
cause of DMD. Although calpain enzymology has
largely progressed, it has been scarcely clariﬁed how
calpain in living DMD muscle ﬁbers contributes to
the progress of atrophy that lasts for many years.
[2-a] Muscle ﬁbers contract even in DMD
patients. Relaxation is a prerequisite to contraction.
At relaxation, cytoplasmic CaDD ions should be
kept below about 10!6molar, where calpain cannot
work. At contraction, they increase to the level of
5 # 10!5.98)
At ﬁrst, calpain was found to be activated by
millimolar level of calcium ions (m-calpain), levels
not found in normal muscle. m-Calpain cannot work
in the living cells. However, in the 1970’s, another
type of calpain was discovered by Imahori that was
activated by micromolar concentration of CaDD ions
(7-calpain), which may work in vivo.7) However, how
can 7-calpain in DMD muscle be regulated by a
minute amount of CaDD ions, where similar concen-
trations of free CaDD ions wax and wane during the
contraction–relaxation cycle? If 7-calpain is respon-
sible for muscle atrophy, muscle proteins must be
digested when the muscle ﬁbers contract, even in the
healthy muscle ﬁbers in which calpain is contained.
Why are only DMD muscle ﬁbers amenable to
atrophy that must be promoted by muscle contrac-
tion? I have sometimes put this question since the
pre-dystrophin era.7) However, no satisfactory an-
swer has so far been obtained.
[2-b] Since the pre-dystrophin era, it has
repeatedly been reported that the content of calcium
increases in DMD muscle.5) Upon contraction, CaDD
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microtears and also probably through calcium
channels activated by membrane stretching as
claimed by Iwata,99) both of which can occur
simultaneously. Calcium can be present in muscle
ﬁbers as either free ions or calcium bound to some
substance or organelle. Because almost all of the
calcium in muscle ﬁbers is present in the bound form,
an increase in the total calcium concentration does
not necessarily mean increase in free CaDD ions,
which is required for activation of calpain.
[2-c] Exogenous CaDD ions must be sequestered
rapidly after their entry into muscle ﬁbers. DMD
patients retain considerable contractile ability for
years even after DMD symptoms appear. This means
that DMD muscles can relax soon after contraction
ceases. In other words, free CaDD ion concentration
must be sequestered to low level by sarcoplasmic
reticulum and mitochondria immediately after the
contraction, even when CaDD ion entry occurs.
Otherwise, prolonged contraction would happen like
in the case of muscle ﬁbers in malignant hyper-
thermia.
[2-d] Young DMD patients suﬀer from severe
muscle cramps and pain mostly during the night after
strenuous movements that are sometimes followed by
myoglobinuria. This phenomenon may be one of the
keys solving the question of when calpain works in
DMD muscle ﬁbers. Unfortunately, the space for
explanation of these phenomena in relation to the
calpain hypothesis has been exhausted.
[3] In addition, we must further consider
whether the target of CaDD ions is solely calpain or
not, and whether calpain activity promoted by a
minute amount of CaDD ions is suﬃcient for inducing
muscle atrophy that progresses during the chronic
course of DMD. CaDD ions might be closely related to
muscular atrophy. However, without microtears,
leakage of the soluble cytoplasmic proteins does not
take place.
5.4. Discussion (6): The gene therapy of
DMD from my viewpoints. Although I did not
work on this ﬁeld, I will very brieﬂy discuss them in
relation to our works (see review51)).
[1] Gene transfer therapy: One of the most
diﬃcult problems in dystrophin gene transfer therapy
is that its cDNA is too large to be carried by
conventional viral vectors. In 1990, Davies100) pro-
posed the use of mini-dystrophin gene derived from
a BMD patient for this purpose. In 1995, I pointed
out that its use is reasonable, because the gene
contains the AB domain and DGBD.51) Feasibility of
recombinant dystrophins having both binding do-
mains to repair mdx mice was experimentally
examined by Takeda45) in 1998 and more extensively
by Chamberlain101) in 2002.
[2] Exon skipping method: In a patient with a
speciﬁed out-of-frame deletion, a small number of
exons close to the deletion can be artiﬁcially skipped
to make an mRNA having a larger but in-frame
deletion.102) Thus, this approach is usually accepted
to change the clinical phenotype from DMD to BMD
without discussing at molecular level. However, we
should recollect the limit of application to the reading
frame rule that I pointed out in Discussion (1). In the
short term, the exon-skipping method should be
eﬀective on the mutations in the rod domain, which
cause the majority of cases of DMD.
From my viewpoints, an eﬀective exon skipping
therapy must result in (1) genetically, avoidance of
degradation of mRNA with NMD and at the same
time (2) phenotypically, to construct the binding
domain of dystrophin to O-DG (DGBD) by changing
the reading frame to produce a functional dystrophin.
Epilogue
Our studies, described above, are divided into
those on the subsarcolemmal cytoskeleton networks
that include the dystrophin–DAP complex and their
application to the muscular dystrophy research.
Although we deduce their functions only from the
evidence obtained by short-term experiments, mus-
cular dystrophy is a group of chronic diseases.
Whether it is relevant to apply such evidence to
understanding such chronic diseases stands as an
unsolved problem. However, I consider that even
though muscular dystrophy is a chronic progressive
disease, its pathological process must be a long-
lasting process with repeated short-term battles
between destructive and repairing processes. To
study active processes of the degenerating disease
might give some clues for understanding the patho-
mechamisms of muscular dystrophy.
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